Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...

Pfizer Inc. has initiated a new clinical study titled A Phase 1, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and ...

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

Rimegepant 75 mg for 52 weeks is well tolerated, with no liver safety signals and a sustained reduction in monthly migraine days, a new extension study shows.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and ...

On May 14, 2025, Biohaven issued a press release “announc [ing] that the Division of Neurology 1 within FDA’s Office of Neuroscience informed the Company that they are extending the PDUFA date ...

Pfizer Inc. is actively advancing its research portfolio with several ongoing clinical studies that could significantly impact its stock performance and market position. One of the notable studies ...